

## Supplementary Information

### **Gold nanoclusters for controlled insulin release and glucose regulation in diabetes**

Yujie Zhang <sup>a</sup>, Mingxin Wu <sup>a</sup>, Wubin Dai <sup>b</sup>, Yingping Li <sup>c</sup>, Xin Wang <sup>a</sup>, Di Tan <sup>a</sup>, Zhilu Yang <sup>d</sup>, Sheng Liu <sup>a</sup>, Longjian Xue <sup>a</sup>, Yifeng Lei <sup>a\*</sup>


<sup>a</sup> The Institute of Technological Sciences & School of Power and Mechanical Engineering, Wuhan University, Wuhan 430072, China

<sup>b</sup> School of Material Science and Engineering, Wuhan Institute of Technology, Wuhan 430205, China


<sup>c</sup> School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China

<sup>d</sup> School of Material Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China


E-mail address: [yifenglei@whu.edu.cn](mailto:yifenglei@whu.edu.cn) (Y.F. Lei)




**Fig. S1** Preparation process of gluconic acid modified bovine insulin (G-Insulin).




**Fig. S2** Gluconic acid modification of insulin (G-Insulin) did not change the structure and bioactivity of pure insulin. (a) CD spectra of pure insulin and G-Insulin. (b) Compare of bioactivity (glucose regulation) of pure insulin and G-Insulin in healthy mice. Drug was intraperitoneally (i.p.) injected into mice for 30 min, then glucose was i.p. injected ( $t = 0$ ), and the blood glucose of mice was monitored thereafter.




**Fig. S3** The induction of type 1 diabetic mouse model using streptozocin (STZ). (a) The glucose changes during the induction of type 1 diabetic mice. The syringes indicated the days of STZ injection. (b) Images of mice cages before and at 10 days after STZ induction.



**Fig. S4** FTIR high-resolution spectra. (a) During the synthesis of GNC-PBA-Ins complex. (b). During the synthesis of GNC-FPBA-Ins complex.



**Fig. S5** XPS high-resolution spectra of F1s during the synthesis of GNC-FPBA-Ins complex.



**Fig. S6** Insulin release from gold nanoclusters over time. (a) Relative amount of insulin release (%) from GNC-PBA-Ins complex. (b) Relative amount of insulin release from GNC-FPBA-Ins complex.

**Table S1** Characteristics of gold nanoclusters by TEM and DLS.

	Size by TEM (nm)	Hydrodynamic size by DLS (nm)	Polydispersity index (PDI)
GNCs	$2.8 \pm 0.5$	$5.2 \pm 1.7$	$0.111 \pm 0.008$
GNC-PBA-Ins	$11.1 \pm 2.0$	$131.3 \pm 8.4$	$0.214 \pm 0.108$
GNC-FPBA-Ins	$14.0 \pm 3.2$	$179.4 \pm 9.7$	$0.282 \pm 0.071$

**Table S2** Drug loading capacity of different nanocarriers.

	Loading capacity of insulin	References
GNC-PBA-Ins	848 $\mu\text{mol}$ insulin per g GNCs	
GNC-FPBA-Ins	951 $\mu\text{mol}$ insulin per g GNCs	
MSNs	64 $\mu\text{mol}$ insulin per g MSNs	1
	7.9 wt % (13.6 $\mu\text{mol}$ insulin per g chitosan-coated particles)	2
Nano-Network	11.4 wt % (19.6 $\mu\text{mol}$ insulin per g alginate-coated particles)	2
Nanocapsules	44.6 wt% (76.8 $\mu\text{mol}$ insulin per g particles)	3

**Supplementary References**

- 1 Y. Zhao, B. G. Trewyn, Slowing, II and V. S. Lin, *J. Am. Chem. Soc.*, 2009, **131**, 8398-8400.
- 2 Z. Gu, A. A. Aimetti, Q. Wang, T. T. Dang, Y. L. Zhang, O. Veiseh, H. Cheng, R. S. Langer and D. G. Anderson, *ACS Nano*, 2013, **7**, 4194-4201.
- 3 Z. Gu, T. T. Dang, M. Ma, B. C. Tang, H. Cheng, S. Jiang, Y. Dong, Y. Zhang and D. G. Anderson, *ACS Nano*, 2013, **7**, 6758-6766.